Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: Implications for clinical use

Stem Cells Translational Medicine

Volumn 2, Issue 12, 2013, Pages 983-992

  Metz, Marianne Z ^a   Gutova, Margarita ^a   Lacey, Simon F ^a   Abramyants, Yelena ^a   Vo, Tien ^a   Gilchrist, Megan ^a   Tirughana, Revathiswari ^a   Ghoda, Lucy Y ^a   Barish, Michael E ^a   Brown, Christine E ^a   Najbauer, Joseph ^a   Potter, Philip M ^b   Portnow, Jana ^a   Synold, Timothy W ^a   Aboody, Karen S ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Cancer therapy; Carboxylesterase; CPT 11; Glioma; Immunogenicity; Irinotecan; Microdialysis; Neural stem cells

Indexed keywords

CARBOXYLESTERASE; CD4 ANTIGEN; CD8 ANTIGEN; FERRIC FERROCYANIDE; FIRTECAN; IRINOTECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME PURIFICATION; GENETIC TRANSDUCTION; GLIOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NATURAL KILLER CELL; NEURAL STEM CELL; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SPECTROPHOTOMETRY; TANDEM MASS SPECTROMETRY;

MUS; ORYCTOLAGUS CUNICULUS;

EID: 84888395554     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0177     Document Type: Article

References (46)

1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6: 583-592.
2. Bidros DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics 2009;6:539-546.
3. Frank RT, Aboody KS, Najbauer J. Strategies for enhancing antibody delivery to the brain. Biochim Biophys Acta 2011;1816:191-198.
4. Gril B, Evans L, Palmieri D et al. Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. Eur J Cancer 2010;46:1204-1210.
5. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
6. Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer 2011;11:352-363.
7. Aboody KS, Najbauer J, Danks MK. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther 2008;15:739-752.
8. Najbauer J, Danks MK, Schmidt NO et al. Neural stem cell-mediated therapy of primary and metastatic solid tumors. In: Bertolotti R, Ozawa K, eds. Progress in Gene Therapy, Autologous and Cancer Stem Cell Gene Therapy. Singapore: World Scientific, 2008:335-372.
9. Gutova M, Shackleford GM, Khankaldyyan V et al. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma. Gene Ther 2013;20:143-150.
10. Thu MS, Najbauer J, Kendall SE et al. Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model. PLoS One 2009;4:e7218.
11. Zhao D, Najbauer J, Annala AJ et al. Human neural stem cell tropism to metastatic breast cancer. STEM CELLS 2012;30:314-325.
12. Zhao D, Najbauer J, Garcia E et al. Neural stem cell tropism to glioma: Critical role of tumor hypoxia. Mol Cancer Res 2008;6:1819-1829.
13. Aboody KS, Najbauer J, Schmidt NO et al. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro Oncol 2006;8:119-126.
14. Danks MK, Yoon KJ, Bush RA et al. Tumortargeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. Cancer Res 2007;67:22-25.
15. Aboody KS, Brown A, Rainov NG et al. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA 2000; 97:12846-12851.
16. Ahmed AU, Thaci B, Alexiades NG et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther 2011;19:1714-1726.
17. Bexell D, Svensson A, Bengzon J. Stem cell-based therapy for malignant glioma. Cancer Treat Rev 2013;39:358-365.
18. Brown AB, Yang W, Schmidt NO et al. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin. Hum Gene Ther 2003;14:1777-1785.
19. Aboody K, Najbauer J, Metz MZ et al. Neural stem cell-mediated enzyme/prodrug therapy for glioma: Preclinical studies. Sci Transl Med 2013;5:184ra59.
20. Wierdl M, Morton CL, Weeks JK et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001;61: 5078-5082.
21. Danks MK, Potter PM. Enzyme-prodrug systems: Carboxylesterase/CPT-11. Methods Mol Med 2004;90:247-262.
22. Pommier Y. Topoisomerase I inhibitors: Camptothecins and beyond. Nat Rev Cancer 2006;6:789-802.
23. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-2242.
24. Wierdl M, Tsurkan L, Hyatt JL et al. An improved human carboxylesterase for enzyme/ prodrug therapy with CPT-11. Cancer Gene Ther 2008;15:183-192.
25. Hatfield MJ, Tsurkan L, Garrett M et al. Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 2011;81: 24-31.
26. Yoon KJ, Krull EJ, Morton CL et al. Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. Mol Cancer Ther 2003;2: 1171-1181.
27. Bencharit S, Morton CL, Howard-Williams EL et al. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 2002;9:337-342.
28. Kim SU. Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 2004;24:159-171.
29. Kim SU, Nagai A, Nakagawa E et al. Production and characterization of immortal human neural stem cell line with multipotent differentiation property. Methods Mol Biol 2008; 438:103-121.
30. Thu MS, Bryant LH, Coppola T et al. Selfassembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging. Nat Med 2012;18:463-467.
31. Morton CL, Potter PM. Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression application to a rabbit liver carboxylesterase. Mol Biotechnol 2000;16:193-202.
32. Bencharit S, Morton CL, Hyatt JL et al. Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition. Chem Biol 2003;10:341-349.
33. Beaufay H, Amar-Costesec A, Thines-Sempoux D et al. Analytical study of microsomes and isolated subcellular membranes from rat liver: 3: Subfractionation of the microsomal fraction by isopycnic and differential centrifugation in density gradients. J Cell Biol 1974;61:213-231.
34. Potter PM, Pawlik CA, Morton CL et al. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11). Cancer Res 1998;58:2646-2651.
35. Gutova M, Najbauer J, Frank RT et al. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. STEM CELLS 2008;26:1406-1413.
36. Brown CE, Starr R, Martinez C et al. Recognition and killing of brain tumor stem-like initiating cells by CD8_cytolytic T cells. Cancer Res 2009;69:8886-8893.
37. Morton CL, Iacono L, Hyatt JL et al. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother Pharmacol 2005;56:629-636.
38. Aboody KS, Bush RA, Garcia E et al. Development of a tumor-selective approach to treat metastatic cancer. PLoS One 2006;1: e23.
39. Zaritskaya L, Shurin MR, Sayers TJ et al. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines 2010;9:601-616.
40. Flax JD, Aurora S, Yang C et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998;16:1033-1039.
41. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12: 278-287.
42. Ricart AD, Tolcher AW. Technology insight: Cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007;4: 245-255.
43. Pasquetto MV, Vecchia L, Covini D et al. Targeted drug delivery using immunoconjugates: Principles and applications. J Immunother 2011;34:611-628.
44. Noble CO, Krauze MT, Drummond DC et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Res 2006;66:2801-2806.
45. Seol HJ, Jin J, Seong DH et al. Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Lett 2011;311: 152-159.
46. Harada Y, Dai P, Yamaoka Y et al. Intracellular dynamics of topoisomerase I inhibitor, CPT-11, by slit-scanning confocal raman microscopy. Histochem Cell Biol 2009;132: 39-46.